Company Overview

Our mission is to improve the lives of people living with diabetes, obesity and other cardiometabolic diseases.

We are applying our proven proprietary technology platform, Arestat®, to develop a portfolio of superior, proprietary products that address areas of high unmet patient need in high value markets.

Our aim is to have multiple options to drive a step-change in company value for our shareholders.

 

Latest Documents

Investor presentation – June 2026

24 June 2026

Arecor Therapeutics plc Form of Proxy

28 April 2026

Arecor Therapeutics plc Notice of Annual General Meeting

28 April 2026

Contact: ir@arecor.com